November 2014

Global Ebola relief effort not reaching rural communities

Wednesday, November 26, 2014

Unprecedented levels of donation to support Ebola-struck Sierra Leone are bypassing many of the places where funding is urgently needed, claim two U.K.-based experts. The independent experts, Dutch sustainability scientist Robert Verkerk, Ph.D., and Sierra Leonean crisis management expert Morris Marah, have just returned from a one-week capacity assessment mission requested by Hon Alpha Kanu, Minister of Information and Communications of Sierra Leone.

[Read More]

CDISC, TransCelerate release new standards for diabetes, cardiovascular disease

Wednesday, November 26, 2014

The Clinical Data Interchange Standards Consortium (CDISC), a global nonprofit, and King of Prussia, Pa.-based nonprofit TransCelerate BioPharma have made available therapeutic area standards for diabetes and cardiovascular (CV) disease areas through the Coalition for Accelerating Standards and Therapies (CFAST), a joint initiative of CDISC and the Critical Path Institute (C-Path).

[Read More]

BioMarin to acquire Prosensa for $680M

Tuesday, November 25, 2014

BioMarin Pharmaceutical, based in San Rafael, Calif., will acquire Prosensa for $17.75 per share, for a total up-front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016, and Europe no later than Feb. 15, 2017, respectively.

[Read More]

CytRx announces partial clinical hold affecting aldoxorubicin clinical trials

Monday, November 24, 2014

CytRx, a biopharmaceutical R&D company specializing in oncology, has received notice from the FDA that its clinical trials for aldoxorubicin have been placed on partial clinical hold. All currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols, but no new patients can be enrolled until the clinical hold is lifted.

[Read More]